3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Melanoma
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
31
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
15
Biopsy
11
trametinib
10
dabrafenib
10
fludarabine phosphate
9
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
Vancomycin
×
Clear all
NCT04208958
2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2
Completed
56 enrolled
11 charts